Skip to main content
News & Events
Podcasts & Webinars
You are here
Collaborate with us in the fight against the spread of monkeypox
The monkeypox (MPX) outbreak is an evolving global health threat. WHO and the Biden administration have declared the outbreak a global health emergency and public health emergency ,...
Novosanis launches Colli-Pee® containing UAS Large Volumes, offering a new solution for oncology research
Today, Novosanis has launched its novel solution for oncology research applications. Together with our sister company DNA Genotek, we have developed a novel stabilization chemistry, UAS TM...
Does volume matter? Impact of collection volumes on detection of biomarkers and HPV DNA in first-void urine
It is well-established that Human Papillomavirus (HPV), the primary cause of cervical cancer can be detected in first-void urine. The study by Laura Téblick (University of Antwerp, Belgium...
New podcast: Urine the 'golden sample' - Why is urine so exciting in cervical cancer prevention?
We recently had the opportunity to interview Dr. Severien Van Keer, a post-doc researcher at the VAXINFECTIO research group, at the University of Antwerp.
Colli-Pee Small Volumes Products CE Marked
Novosanis achieved two major milestones - our Colli-Pee ® Small Volumes product line is now CE-Marked.
Home-based urine sampling for STIs
Novosanis attended IUSTI2018 from June 26 to June 30 in Dublin, Ireland. Our Colli-Pee device suited for first-void urine collection allowing for improved detection of STIs was on display...
Novosanis’ medical device Colli-Pee™ US FDA listed
Colli-Pee US FDA listed
Novosanis supports Urology week - Prostate Cancer detection
Prostate cancer is the most common male cancer, with around 400,000 new cases every year in Europe.
Novosanis supports Urology Week Day#2
For a healthy life
Novosanis supports Urology Week
Urology week is an initiative from the European Association for Urology (EAU) that tries to raise awareness for urological care and its importance in improving quality of life.
When reality hits you hard-listen to Lady Ganga's story.
This is the story of Michele Baldwin, a 45-year-old mother of three who was diagnosed with late-stage cervical cancer.
GeneFirst mentions their collaboration with Novosanis in their article on HPV detection with genotyping
GeneFirst Ltd collaborates with Novosanis